
EnteroBiotix - Gut Liver Brain Axis Microbiome
The gut-liver-brain axis describes the interplay of immune, metabolic and neuroendocrine biology that is increasingly being recognised as a potential therapeutic target.
The gut microbiome and the gut-liver axis are thought to be of prime importance in the pathophysiology underpinning liver disease. Multiple studies have shown that there are reductions in microbiome diversity and an imbalance between healthy and pathogenic gut bacteria, with increased proportions of pro-inflammatory species, in patients with various forms of liver disease, including cirrhosis and hepatitis.
Hepatic encephalopathy
IMT has a beneficial impact on patients with Hepatic Encephalopathy (HE) with studies showing sustainable changes to the gut microbiome that correlate with improved cognitive performance, reduced hospitalisation rates and mortality
Alcoholic liver disease
IMT improves liver disease severity scores and overall survival at one year (87.5% vs 33.3%) when compared with historical controls in patients with steroid-ineligible severe alcoholic hepatitis
Primary sclerosing cholangitis
IMT has been piloted in primary sclerosing cholangitis (PSC) and associated with significant increases in microbiome biodiversity in addition to improvements in alkaline phosphatase, a biomarker for disease severity